Chapter Titles
|
Formats
|
|
| Introduction (1:40 MIN.) |
|
|
|
|
|
| Chapter 1–Rationale for Targeted B-Cell Depletion in Rheumatic Disease, Gregg J. Silverman, MD (13:09 MIN.) |
|
|
|
|
|
| Chapter 2–Anti-CD20 Therapy: MOA and Immunobiologic Implications, Gregg J. Silverman, MD (18:09 MIN.) |
|
|
|
|
|
| Chapter 3–Anti-CD20 Therapy in RA: Clinical Response and Safety, Marc D. Cohen, MD (25:04 MIN.) |
|
|
|
|
|
| Chapter 4–Anti-CD20 Therapy in RA: Special Biologic Considerations, Marc D. Cohen, MD (8:44 MIN.) |
|
|
|
|
|
| Chapter 5–Newer Agents Targeting B Cells, Gregg J. Silverman, MD (10:24 MIN.) |
|
|
|
|
|
| Chapter 6–Targeting B Cells in SLE, Gregg J. Silverman, MD (14:19 MIN.) |
|
|
|
|
|
| Chapter 7–Targeting B Cells in Vasculitis and Sjögrens Syndrome, Marc D. Cohen, MD (20:41 MIN.) |
|
|
|
|
|
= 
= 
= 
= 
